GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

GlaxoSmithKline’s (GSK ... expansive capabilities, client focus and culture make it a unique platform from which to advance health care worldwide, so I am incredibly excited to be part of ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities ...

Here's today's NYT Mini Crossword answer. These answers will help you solve New York Times' popular crossword game, Mini ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Together with GSK, the Boston-based research team will ... cells with stem cell-derived mesenchymal cells. These advanced co-culture models will mimic the complex interactions between different ...